4-氯吡啶-3-磺酸 | 51498-38-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 4-氯吡啶-3-磺酸
• 中文别名: 4-氯吡啶-3-磺酰酸
• 英文名称: Chlor-(4)-pyridin-sulfonsaeure-(3)
• 英文别名: 4-chloro-pyridine-3-sulfonic acid；4-Chloropyridin-1-ium-3-sulfonate；4-chloropyridin-1-ium-3-sulfonate
• CAS: 51498-38-5
• 化学式: C₅H₄ClNO₃S
• mdl: MFCD01928012
• 分子量: 193.611
• InChiKey: CFUZNCDDZQWQBU-UHFFFAOYSA-N

物化性质

• 熔点：
  318-321 °C
• 密度：
  1.649±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P301+P330+P331,P303+P361+P353,P363,P304+P340,P310,P321,P260,P264,P280,P305+P351+P338,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H314

文献信息

• Benzo- and azabenzodithiazole compounds
  申请人：Sang Xiaopeng

  公开号：US20050101646A1

  公开（公告）日：2005-05-12

  The present invention provides compounds of formula I or a pharmaceutically acceptable salt, solvate, prodrug or isomer thereof and compounds of the formula or a pharmaceutically acceptable salt, solvate, prodrug or isomer thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了公式I的化合物或其药学上可接受的盐、溶剂化物、前药或异构体以及公式的化合物或其药学上可接受的盐、溶剂化物、前药或异构体。本发明的化合物通过抑制HER1、HER2和HER4等生长因子受体的酪氨酸激酶活性，因此可作为抗增殖剂使用。这些化合物还可用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
• [EN] THROMBIN INHIBITORS<br/>[FR] INHIBITEURS DE LA THROMBINE
  申请人：NOVARTIS AG

  公开号：WO1997046553A1

  公开（公告）日：1997-12-11

  (EN) The present invention provides a compound of general formula (I) in which Y is a primary or secondary amino group; R2 is the residue of a natural or synthetic amino acid; R3 is hydrogen or a C1-C8 alkyl chain which may be substituted by hydroxy or halogen; and X is (CH2)n where n is 1, 2, or 3, or is CH2N or represents a fused phenyl ring which is optionally substituted by one or two methoxy groups or a salt thereof.(FR) L'invention concerne un composé de formule générale (I), ou son sel, formule dans laquelle Y est un groupe amino primaire ou secondaire; R2 est le résidu d'un acide aminé naturel ou synthétique; R3 est hydrogène ou une chaîne alkyle C1-C8 qu'on peut substituer par hydroxy ou halogène; et X est (CH2)n où n est égal à 1, 2 ou 3, ou bien est CH2N ou représente un noyau phénylique condensé éventuellement substitué par un ou deux groupes méthoxy.

  本发明提供了通式（I）的化合物，其中Y是一级或二级氨基团；R2是天然或合成氨基酸的残基；R3是氢或C1-C8烷基链，可以被羟基或卤素取代；X是（CH2）n，其中n为1、2或3，或者是CH2N或代表一个融合的苯环，该环可以选择地被一个或两个甲氧基取代，或其盐。
• BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
  申请人：Wanaski Stephen

  公开号：US20120004225A1

  公开（公告）日：2012-01-05

  The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  本发明提供了丁苯噻唑、呋塞米、匹利他酯、氮杂呋喃硫脲和托瑞米特的类似物以及包含这些类似物的组合物。本发明还提供了含有这些丁苯噻唑、呋塞米、匹利他酯、氮杂呋喃硫脲和托瑞米特类似物的药物组合物以及它们的使用方法。所有这些类似物特别适用于治疗和/或预防涉及Na+K+Cl−共转运体或GABAA受体的疾病，包括但不限于成瘾障碍、阿尔茨海默病、焦虑障碍、腹水、自闭症、躁郁症、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、失眠、缺血、偏头痛、带前兆的偏头痛、神经痛、伤害性神经痛、眼部疾病、疼痛、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫、耳鸣和戒断综合症。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20140288070A1

  公开（公告）日：2014-09-25

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  本文描述了化合物及其盐、制剂、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述的化合物或其盐、制剂、共轭物、衍生物、形式至少对一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述的化合物具有抑制Ras突变细胞系增殖的活性。还描述了使用它们治疗疾病和病症的方法，包括与B-Raf V600E突变蛋白激酶活性相关的疾病和病症，包括黑色素瘤、胶质瘤、多形性胶质母细胞瘤、毛细胞星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠道间质瘤、胆道癌和胆管癌。还描述了使用它们治疗与c-Raf-1蛋白激酶活性相关的疾病和病症的方法，包括急性疼痛、慢性疼痛或多囊肾病。
• BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
  申请人：NeuroPro Therapeutics, Inc.

  公开号：US20150080350A1

  公开（公告）日：2015-03-19

  The present invention provides bumetanide, analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma. Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  本发明提供了丁苯酞、类似物和包含这些类似物的组合物。本发明还提供了含有这些丁苯酞、类似物的药物组合物以及它们的使用方法。这些类似物特别适用于治疗和/或预防涉及Na+K+Cl−共转运体或GABAA受体的疾病，包括但不限于成瘾性障碍、阿尔茨海默病、焦虑症、腹水、自闭症、双相情感障碍、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、失眠症、缺血、偏头痛、伴有先兆的偏头痛、神经痛、痛觉性神经痛、眼部疾病、疼痛、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫、耳鸣和戒断综合征。